. . . according to the results of the large-scale, randomized Women's Antioxidant Cardiovascular Study.
. . according to the results of the large-scale, randomized Women's Antioxidant Cardiovascular Study. The study tested the effects of 500 mg/d of ascorbic acid, 600 IU of vitamin E every other day, and 50 mg of beta carotene every other day on cardiovascular (CV) events (i.e., myocardial infarction, stroke, coronary revascularization, or CV disease death) in over 8,000 women at high risk for CV disease.
In this first trial to examine the effects of ascorbic acid alone on CV disease prevention, more than 9 years of follow-up revealed no statistically significant benefits associated with any of the antioxidants studied either alone or in combination, with the exceptions of a marginally significant reduction in CV events among women with prior CV disease taking vitamin E (RR 0.89; 95% CI, 0.79-1.00; P=0.04) and a possible reduction in stroke among women taking both vitamins C and E (P=0.03).
On a positive note, no detrimental effects from any of these agents on total or CV disease mortality surfaced either.
Commentary from Nanette F. Santoro, MD, Professor and Director, Division of Reproductive Endocrinology, Department of Ob/Gyn and Women's Health, Albert Einstein College of Medicine, Bronx, NY.
The Women's Antioxidant Cardiovascular Study has found that supplemental vitamin C at 500 mg a day and vitamin E at 600 IU every other day did not prevent cardiovascular disease in women. This study complements prior work that has reported ineffectiveness or even harm from dietary supplements. It appears that eating foods rich in these nutrients is superior to taking them as supplements.
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More